Conclusion
Based on our results, we conclude that there are significant differences
in the use of VV-ECMO in treating ARDS due to COVID-19 to treating ARDS
due to influenza. COVID-19 patients appear to be at a higher risk of
bacterial superinfection, and prevention and control of bacterial
infections may be critical in improving survival. More research is
needed to understand the efficacy and risks of using ECMO to treat cases
of COVID-19.
Table 1 : Contraindications for ECMO in COVID-19